NHS Stock

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on February 28, 2025, has a record date of February 18, 2025, and has an ex-date of February 18, 2025.

NEW YORK , Dec. 31, 2024 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on January 31, 2025, has a record date of January 15, 2025, and has an ex-date of January 15, 2025.

The Neuberger Berman High Yield Strategies offers a high yield of 14.42%, better than the domestic junk bond index but with higher volatility. Despite its high yield, the market doubts the fund's ability to sustain its payout, implying a potential 35% distribution cut. The fund's recent performance has been disappointing, with a 7.72% share price decline and underperformance compared to both investment-grade and junk bonds.

LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, today announced that NHS England has implemented the commissioning of Evkeeza (evinacumab) following the National Institute for Health and Care Excellence (NICE) final guidance in September. The use of Evkeeza in eligible people aged 12 years and older will be routinely commissioned by NHS England in line with the NICE TA and will be available in seven hospital trusts in England. In addition, prior approval forms are in place to enable access for children aged 5 to 11 years, via the NHS England Commissioning Medicines for Children policy.

Online searches for Eli Lilly and Co's (NYSE:LLY) weight loss and diabetes drug Mounjaro have soared more than four-fold since the NHS received approval for weight loss programmes last week. UK drug regulator NICE gave the green light for it to be prescribed alongside diet and exercise advice from March 2025, but said a full roll-out to everyone who wants it will take twelve years.

NEW YORK , Nov. 29, 2024 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on December 31, 2024, has a record date of December 16, 2024, and has an ex-date of December 16, 2024.

NEW YORK , Oct. 31, 2024 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on November 29, 2024, has a record date of November 15, 2024, and has an ex-date of November 15, 2024.

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.

I recommend holding Neuberger Berman High Yield Strategies for its 12.8% yield, despite its current high premium to NAV. The NHS closed-end fund benefits from lower interest rates, which increase bond prices, and has outperformed peers in total return YTD. The fund's steady monthly distributions and defensive portfolio make it a compelling high-yield income option.